Petros pharmaceuticals to pursue 505(b)(2) pathway for h-100, company's novel topical investigational treatment for peyronie's disease which impacts more than 1 in 10 men in the us

Company is developing h-100 as potentially the first fda-approved, nanoparticle-based topical treatment designed to provide improved and sustained local medication permeation against peyronie's disease, which is currently predominantly treated surgically, or by a series of injections company is developing h-100 as potentially the first fda-approved, nanoparticle-based topical treatment designed to provide improved and sustained local medication permeation against peyronie's disease, which is currently predominantly treated surgically, or by a series of injections
PTPI Ratings Summary
PTPI Quant Ranking